Minetta Liu, MD, discusses the limitations of radiology in the treatment of patients with metastatic breast cancer.
Minetta Liu, MD, breast cancer specialist, Mayo Clinic, Rochester, Minnesota, discusses the limitations of radiology in the treatment of patients with metastatic breast cancer.
Liu says that the key in metastatic breast cancer is trying to stay ahead and determine the right time to change therapy. Currently, the gold standard for measuring this is by using imaging, such as CAT scans, MRIs, and ultrasounds.
However, Liu says, it is difficult for a radiologist to measure these tumors in a reproducibleway. A study in several solid tumors found a variability of 15% when separate radiologists were asked to look at identical images. Surprisingly, Liu says, the variation was even higher when the same radiologist looked at the same picture just one week later.
Liu says that a better, more reliable method must be determined. Counting circulating tumorcells (CTCs) are more reliable and reproducible and the variation is only on the order of 1% to 5%.
Although no test is perfect, having multiple, reliable tools would help physicians to measure the progression of metastatic breast cancer, Liu says.
Clinical Pearls
Therapy Type and Site of Metastases Factor into HR+, HER2+ mBC Treatment
December 20th 2024During a Case-Based Roundtable® event, Ian Krop, MD, and participants discussed considerations affecting first- and second-line treatment of metastatic HER2-positive breast cancer in the first article of a 2-part series.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
Imlunestrant Improves PFS in ESR1-Mutant Advanced Breast Cancer
December 13th 2024The phase 3 EMBER-3 trial showed imlunestrant improved PFS over SOC endocrine therapy in ER-positive, HER2-negative advanced breast cancer with ESR1 mutations, though not significantly in the overall population.
Read More